MétaCan
Menu
Back to cohort

P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A

2023· article· en· W4385707424 on OpenAlexaff
Paula Rodríguez‐Otero, Hang Quach, Katja Weisel, Andrea Viqueira, Shen‐Wu Wang, Phineas T. Hamilton, Tao Xie, Thomas O'Brien, Nizar J. Bahlis

Bibliographic record

VenueHemaSphere · 2023
Typearticle
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsInstitute of Cancer ResearchUniversity of Calgary
Fundersnot available
KeywordsMultiple myelomaCD38MedicinePlasma cellInternal medicineOncologyBortezomibExome sequencingCohortImmunologyBone marrowBiologyGenePhenotypeGeneticsStem cell

Abstract

fetched live from OpenAlex

Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: MagnetisMM-3 (NCT04649359) is an open-label, multicenter, non-randomized phase 2 study of elranatamab monotherapy in patients with multiple myeloma refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 antibody. Aims: This analysis examined molecular correlates of elranatamab response and resistance in patients naïve to B-cell maturation antigen (BCMA)-directed therapy (Cohort A). Methods: Bone marrow aspirate (BMA) samples collected at screening were analyzed by whole exome and whole transcriptome sequencing. To investigate the contribution of the tumor microenvironment in elranatamab response, the abundance of cell types in the BMA samples collected at screening was estimated using single sample gene set enrichment analysis (ssGSEA) of LM22 cell type signatures. For this analysis, response was defined as a best overall response of very good partial response or better, and non-response was defined as partial response or worse. Results:TNFRSF17 (BCMA encoding gene) expression correlated with markers of disease burden: levels increased with disease stage (with progressively higher levels in R-ISS stages I, II, and III; p=0.014), were higher in patients with high-risk cytogenetics (p=0.002), and correlated with plasma cell content in BMA samples (ρ=0.80; p<10-10) (Figure). TNFRSF17 expression trended higher in non-responders (p=0.08), but this trend was diminished when adjusting for disease burden. These findings suggest that TNFRSF17 expression in bulk bone marrow samples is associated with higher disease burden and likely poorer response. According to ssGSEA of LM22 cell types, plasma cells in BMA were associated with non-responders (p=0.03). Further multivariable modeling (controlling for plasma cell content) revealed additional cell types associated with response, including macrophages and monocytes, which were associated with poor outcome. Patients with both low plasma and low myeloid cells were most likely to respond. Genome wide copy number analysis showed that TNFRSF17 locus amplification was associated with non-response (p=0.008). Chromosomal alterations associated with non-response were identified, including genomic loci known to define high-risk multiple myeloma (eg, 1q21+) and loci not known to be associated with high-risk multiple myeloma (eg, 17q21+ and 6p21+). Summary/Conclusion: Genomic analysis of BMA samples from MagnetisMM-3 identified an association between higher TNFRSF17 expression in the tumor microenvironment and unfavorable outcomes, likely due to its surrogacy with increased tumor burden. Features of high-risk disease were also associated with lack of response to elranatamab. Adjusting for tumor cell content revealed additional aspects of the tumor microenvironment associated with poor response, including increased myeloid cell populations. Lastly, alterations in specific genomic loci were also associated with response, consistent with tumor intrinsic features influencing elranatamab response.Keywords: Multiple myeloma, Myeloma, Clinical trial, Gene expression

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.028
GPT teacher head0.365
Teacher spread0.336 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueHemaSphereSame topicMultiple Myeloma Research and TreatmentsFrench-language works237,207